Stay updated with breaking news from Mitochondrial Targeting Sequence. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
GenSight Biologics shares resume trading today Over €9.2 million offering of ABSA composed of a reserved offering aimed at specialized investors and a private placement More than 50% of the...
Press Release GenSight Biologics Announces the Filing of its 2023 Universal Registration Document Paris, France, April...
Advanced discussions ongoing to secure financing until resumption of early access program expected in Q3 2024 Full alignment sought with regulatory agencies prior to launch of a global Phase III...
PARIS--(BUSINESS WIRE)--Mar 12, 2024--
16.01.2024 - Regulatory News: The Board of Directors of GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (the 'Company'), a biopharma company focused on developing and commercializing innovative gene therapies for retinal ...